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Risk of QT prolongation 
through drug interactions 
between hydroxychloroquine 
and concomitant drugs prescribed 
in real world practice
Byung Jin Choi1,6, Yeryung Koo1,6, Tae Young Kim1, Wou Young Chung2, Yun Jung Jung2, 
Ji Eun Park2, Hong‑Seok Lim3, Bumhee Park1,4* & Dukyong Yoon1,5* 
Hydroxychloroquine has recently received attention as a treatment for COVID‑19. However, it may 
prolong the QTc interval. Furthermore, when hydroxychloroquine is administered concomitantly 
with other drugs, it can exacerbate the risk of QT prolongation. Nevertheless, the risk of QT 
prolongation due to drug‑drug interactions (DDIs) between hydroxychloroquine and concomitant 
medications has not yet been identified. To evaluate the risk of QT prolongation due to DDIs between 
hydroxychloroquine and 118 concurrent drugs frequently used in real‑world practice, we analyzed 
the electrocardiogram results obtained for 447,632 patients and their relevant electronic health 
records in a tertiary teaching hospital in Korea from 1996 to 2018. We repeated the case–control 
analysis for each drug. In each analysis, we performed multiple logistic regression and calculated the 
odds ratio (OR) for each target drug, hydroxychloroquine, and the interaction terms between those 
two drugs. The DDIs were observed in 12 drugs (trimebutine, tacrolimus, tramadol, rosuvastatin, 
cyclosporin, sulfasalazine, rofecoxib, diltiazem, piperacillin/tazobactam, isoniazid, clarithromycin, 
and furosemide), all with a p value of < 0.05 (OR 1.70–17.85). In conclusion, we found 12 drugs that 
showed DDIs with hydroxychloroquine in the direction of increasing QT prolongation.
The COVID-19 pandemic has caused more than 14 million cases of the disease worldwide as of July 22,  20201, 
and to the best of our knowledge, no drug has been proven to target this virus to date. Meanwhile, one of the 
many attempts with off-label practice that received attention for treating COVID-19 was the use of hydroxy-
chloroquine, a conventional antimalarial  treatment2,3.
However, several studies have reported the cardiotoxic side effects of  hydroxychloroquine4. Furthermore, 
when hydroxychloroquine was administered together with other drugs such as azithromycin, it can exacerbate 
the risk of QT prolongation due to drug-drug interactions (DDIs)5–8.
Hydroxychloroquine is also commonly used for some chronic diseases such as rheumatoid  arthritis9 or 
systemic lupus  erythematosus10,11. In these chronic diseases, hydroxychloroquine is usually taken over a long 
term, so it is often used in combination with other drugs. However, the risk of QT prolongation caused by DDIs 
between hydroxychloroquine and other medications has not yet been assessed comprehensively. The lack of 
evidence on the level of QT prolongation risk caused by DDIs poses a challenge to both physicians and regula-
tors in treating patients.
To analyze the risk of QT prolongation caused by DDIs retrospectively from the perspective of real-world data, 
a large amount of electrocardiogram (ECG) results and drug prescription records are needed. Drug prescription 
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data are usually easily accessible in electronic medical records (EMR) but extracting QTc interval information 
from the ECG results stored in hospital information systems could be a barrier to conducting large-scale studies 
with ECG data. We have made an effort to collect portable ECG results from inpatients and outpatients for the 
last few  years12. In this database, ECG parameters such as RR, PR, QRS, QT, and QTc intervals were extracted 
from raw ECG signals. The ECG database enabled us to conduct a study to provide direct evidence of QT pro-
longation caused by DDIs between hydroxychloroquine and other co-medications.
In this study, we aimed to evaluate the risk of QT prolongation caused by DDIs between hydroxychloro-
quine and other frequently used co-medications in real-world practice by conducting large-scale retrospective 
case–control studies.
Methods
This retrospective study was conducted based on EMR data. The Institutional Review Board of Ajou University 
Hospital approved the study (IRB No. AJIRB-MED-MDB-19-406) and waived the requirement for informed 
consent because only anonymized data were used retrospectively. All research was performed in accordance 
with relevant guidelines and regulations.
Data sources. We used the EMR database of Ajou University Hospital, a tertiary teaching hospital in Korea, 
recorded between January 1996 and May 2018. The database included 177,841,556 prescriptions, 379,994,144 
laboratory test results, and 3,024,891 patient demographics.
QTc values from the same observational period were extracted from the local ECG repository in the MUSE 
 system12,13. The ECG report typically contains both alphanumeric values and waveform graphs. The QTc data 
were extracted by parsing alphanumeric data from the PDF data extracted from the ECG repository using the 
web-scraping technique in our previous  study12. This ECG database contains 1,040,752 ECG results from 447,632 
patients as of January 2018 (Fig. 1). Patients whose clinical and ECG data were recorded in both EMR and our 
ECG repository were finally enrolled in this analysis.
Study design and population. This study consisted of a series of retrospective case–control studies. In 
each study, we assessed the risk of QT prolongation due to DDI between hydroxychloroquine and one of the 
drugs (target drug) concomitantly used. We iterated this process for selected candidate drugs used in the subject 
hospital. The differences in drug use between patients with QT prolongation and those without QT prolongation 
were compared (Fig. 1). QT prolongation was defined as an event where corrected QT (QTc), calculated using 
the Bazett formula, was greater than 450 ms for males and 460 ms for females.
We excluded the following ambiguous ECG results: (1) automatically duplicated ECG measurements known 
as systemic errors (n = 84), and (2) sequentially measured ECG performed within 30 min, because these may 
reflect that the previous measurement could be an error (n = 47,700). We then randomly selected one ECG result 
per patient (n = 447,632). ECGs without sex or age information in the EMR and ECGs with age outliers (age < 0 
and age > 120) were removed (n = 3057).
Selection of candidate drugs for DDI risk analysis. To select candidate drugs, we first extracted all 
drugs prescribed concomitantly with hydroxychloroquine in the window of interest (from 7 days prior to the 
date of ECG measurement) from the EMR. Then, drugs used concomitantly more than 10 times were included 
in the analysis. The list of selected drugs and their frequency of concurrent use are provided in Supplementary 
Table S1 online.
Definition of covariates. The following variables were included in the analysis to adjust for possible con-
founding factors on QT prolongation: (1) demographic information including sex and age at the ECG exami-
nation date, (2) comorbidities recorded in the EMR within a year before the ECG measurement date based 
on the International Classification Disease-10 (ICD-10). These comorbidities included myocardial infarction, 
congestive heart failure, ischemic stroke, hemorrhagic stroke, diabetes mellitus, hypothyroidism, renal disease, 
AIDS/HIV, alcohol abuse, drug abuse, liver disease, and severe liver disease; (3) the latest serum potassium and 
calcium levels within a year before the ECG measurement date. In patients without laboratory test results within 
1 year before the ECG examination date, we imputed the missing values using the median value from patients 
of the same age group divided by 10-year intervals, and (4) the use of other drugs known to increase the risk of 
QT prolongation prescribed within 7 days before ECG measurement. The list of medications and comorbidities 
applied as parametric covariates is shown in Supplementary Table S2 online.
Subgroup analysis. Because the risk of QT prolongation varies according to age and sex, we conducted a 
subgroup analysis. For this, we divided the subjects by sex (male and female) and age (age equal to or under 60 
and age over 60). In this subgroup analysis, we included all drugs that were included in the main analysis.
Statistical analysis. We compared the demographic characteristics of the subjects, laboratory test results, 
comorbidities present, medication use, and year of the ECG measurement between the QT prolongation cases 
and controls using Pearson’s chi-square tests (for categorical data) and independent two-sample t tests (for con-
tinuous data).
We adopted multiple logistic regression with interaction terms to investigate the DDI. The detailed logit 
model for the jth drug in the candidate drug list is as follows:
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where P j(Yi = 1) is the ith subject’s QT prolongation probability, α is the intercept, x
(chl)
i  is the ith study subject’s 
use of hydroxychloroquine, x
(drugj)




i  is the interaction 
term between x(chl)i  and x
(drugj)
i  , and x
(cov)
ik  is the kth covariate of the ith subject.
In the regression model, we calculated the coefficient of the interaction term (β3), odds ratio, and p value. 
When the p value of β3 was less than 0.05, we judged that hydroxychloroquine and the ith candidate drug had 
a statistically significant DDI.
For all drugs in the candidate drug lists, the multiple logistic regression was repeated iteratively to investigate 
























Figure 1.  Overview of the study process. Among 1,040,752 ECG results, 992,968 ECGs that have no duplicated 
or repeated measurements were extracted and selected one ECG for one patient with sex and age information 
with no age outlier. Total of 444,475 ECG results were enrolled and divided into QT prolongation case 
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To visualize the interactions of statistically significant DDI drugs, we plotted the changes in the logit value 
of QT prolongation (Y-axis) according to the use of the target drug (X-axis) and that of hydroxychloroquine.
Software. Data management was performed using Azure data studio version 1.19.0, and all statistical analy-
ses were conducted using Python version 3.7 and the Python package Statsmodel version 0.11.1. The Python 
packages Matplotlib version 3.2.2, and seaborn Python packages version 0.10.0 were also used for visualization 
of the data and results.
Results
Baseline characteristics. The total number of subjects included in the final analysis was 444,575. Among 
them, the QT prolongation case group had 58,258 subjects and the control group had 386,317 subjects. Of the 
total patients, 218,997 were men and 225,578 were women. 1417 patients received hydroxychloroquine within 
7 days before their ECG examination date. The baseline characteristics of the patient group are summarized in 
Table 1.
Drug–drug interaction analysis. We analyzed drugs through iterative multiple regression analysis with 
the interaction terms. As shown in Table 2, the ORs for the interaction terms were significant in the analysis of 
Table 1.  Baseline characteristics of the study group. Table shows baseline characteristics comparison between 
a group with QT prolongation and a group without QT prolongation. *Mark indicates that the p value was 




Hydroxychloroquine, n (%) 266 (0.5) 1151 (0.3) < 0.001
Sex < 0.001
Men, n (%) 29,932 (51.4) 189,065 (48.9)
Women, n (%) 28,326 (48.6) 197,252 (51.1)
Age, mean (SD) 54.9 (20.8) 42.5 (20.4) < 0.001*
Age, n (%) < 0.001
–29 102,645 (26.6) 6996 (12.0)
30–39 68,163 (17.6) 5417 (9.3)
40–49 69,555 (18.0) 8289 (14.2)
50–59 59,192 (15.3) 10,355 (17.8)
60–69 47,296 (12.2) 10,767 (18.5)
70–79 30,296 (7.8) 11,027 (18.9)
–80 9170 (2.4) 5407 (9.3)
Laboratory test result
Potassium, mean (SD) 4.0 (0.6) 4.1 (0.4) < 0.001*
Calcium, mean (SD) 8.9 (0.7) 9.2 (0.5) < 0.001*
Comorbidity
Myocardial infarction, n (%) 1733 (3.0) 3519 (0.9) < 0.001
Congestive heart failure, n (%) 1795 (3.1) 2397 (0.6) < 0.001
Ischemic stroke, n (%) 2462 (4.2) 6366 (1.6) < 0.001
Hemorrhagic stroke, n (%) 1506 (2.6) 2199 (0.6) < 0.001
Diabetes mellitus, n (%) 3341 (5.7) 12417 (3.2) < 0.001
Hypothyroidism, n (%) 246 (0.4) 1977 (0.5) 0.005
Renal disease, n (%) 2172 (3.7) 3022 (0.8) < 0.001
AIDS/HIV, n (%) 27 (0.0) 125 (0.0) 0.114
Obesity, n (%) 94 (0.2) 2285 (0.6) < 0.001
Drug abuse, n (%) 194 (0.3) 390 (0.1) < 0.001
Liver disease, n (%) 1972 (3.4) 2703 (0.7)  < 0.001
Year of QTc diagnosis (ref. year 1995–1999)
1995–1999 28,246 (7.3) 1921 (3.3)
2000–2004 69,420 (18.0) 5172 (8.9)
2005–2009 89,273 (23.1) 10,262 (17.6)
2010–2014 102,983 (26.7) 16,396 (28.1)
2015–2019 96,395 (25.0) 24,507 (42.1)
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trimebutine, tacrolimus, tramadol, rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, piperacillin/
tazobactam, isoniazid, clarithromycin, and furosemide.
In 8 of these 12 drugs (trimebutine, tramadol, rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, 
and isoniazid), DDIs were present in the direction of increasing the risk of QT prolongation, even though the 
risk of QT prolongation was not observed with the use of these drug alone. In piperacillin, clarithromycin, and 
furosemide, we observed a statistically significantly higher risk of QT prolongation even when they were used 
alone, where DDIs were also observed. The results of the analysis of all medications are included in Supplemen-
tary Table S3 online. The full result including ORs of all covariates on tramadol is presented in Supplementary 
Table S4 online as an example of iterative multiple logistic regression.
In each regression model, the average logit value of the intercept was − 2.7. This corresponds to a QT prolon-
gation probability of 0.07 when all other variables were set as 0 (i.e., having no risk factor and no exposure to both 
hydroxychloroquine and target drug). The average logit value when using hydroxychloroquine alone without any 
other risk factors was − 2.5 (QT prolongation probability of 0.08). As shown in Fig. 2, the logit value (probability 
of QT prolongation occurrence) increased when hydroxychloroquine and the target drug were administered at 
the same time compared to expected additive effect of the two drugs in all 12 drugs. This means that all 12 drugs 
have DDIs in the direction of increasing the risk of QT prolongation.
Subgroup analysis. We divided the patient group into four subgroups according to sex and age. We then 
investigated whether the drugs used in each subgroup showed significant (p < 0.05) DDIs with hydroxychloro-
quine. We found that five drugs (tramadol, trimebutine, nifedipine, sulfasalazine, and rofecoxib) showed signifi-
cant (p < 0.05) DDIs with hydroxychloroquine in the female subgroup, and three drugs (tacrolimus, paraceta-
mol, and propacetamol) showed significant (p < 0.05) DDIs in the male patient group. Nine drugs (rosuvastatin, 
tacrolimus, sulfasalazine, trimebutine, ranitidine, ranitidine, diltiazem, celecoxib, paracetamol, and aceclofenac) 
showed DDIs with hydroxychloroquine in the group under 60 years of age. In the elderly group over 60 years 
old, no drug was significant (p < 0.05), but five drugs (clopidogrel, bisoprolol, furosemide, tramadol, and trime-
butine) implied the possibility of a DDI (p < 0.1). The ten drugs with the highest probability of interaction for 
each subgroup are described in Table 3.
Discussion
Using EMRs obtained at a tertiary hospital, we investigated DDIs between hydroxychloroquine and 118 other 
drugs. We observed significant (p < 0.05) DDIs in 12 drugs. Among them, piperacillin/tazobactam, clarithro-
mycin, and furosemide showed a risk of QT prolongation in individual treatment, and a DDI in the direc-
tion of increasing QT prolongation risk was also observed. However, for eight drugs (trimebutine, tramadol, 
rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, and isoniazid), DDI was present in the direction 
of increasing the risk of QT prolongation, even though the QT prolongation risk of individual drugs was not 
significant (p < 0.05).
It is well known that hydroxychloroquine can cause QT  prolongation14,15. With the concern that DDIs between 
hydroxychloroquine and other drugs may exacerbate side effects such as this, several studies on the DDI of 
hydroxychloroquine have been  investigated14,16,17. However, existing studies have selectively studied the DDI 
between hydroxychloroquine and some drugs that captured the attention of clinicians, such as immunosup-
pressants or  antibiotics16–19.
Table 2.  Odds ratio of single drug use and interaction with hydroxychloroquine from each multiple 
logistic regression. Detailed analysis results of 12 drugs whose interaction term with hydroxychloroquine 
was statistically significant (p > 0.05) in linear regression. ‘Single drug use’ columns show the Odds ratio 
(OR), 95% Confidence interval (95% CI), and p value of the analyzed drug in the linear regression, and 
’Interaction with hydroxychloroquine’ columns show OR, 95% CI, and the p value of the interaction term with 
hydroxychloroquine. p value was calculated through the two-sided T test.
Single drug use Interaction with hydroxychloroquine
OR 95% CI p value OR 95% CI p value
Trimebutine 0.84 0.76–0.94 < 0.001 2.17 1.33–3.53 < 0.001
Tacrolimus 0.75 0.58–0.97 0.03 2.27 1.31–3.93 < 0.001
Tramadol 0.98 0.90–1.07 0.66 1.70 1.24–2.34 < 0.001
Rosuvastatin 0.93 0.86–1.01 0.07 2.80 1.40–5.58 < 0.001
Cyclosporin 0.52 0.38–0.70 < 0.001 8.06 3.05–21.29 < 0.001
Sulfasalazine 0.81 0.57–1.16 0.25 2.12 1.19–3.80 0.01
Rofecoxib 0.35 0.12–0.97 0.04 8.89 1.56–50.7 0.01
Diltiazem 0.84 0.77–0.90 < 0.001 3.15 1.29–7.72 0.01
Piperacillin 1.34 1.16–1.56 < 0.001 17.85 2.10–151.94 0.01
Isoniazid 1.20 0.98–1.47 0.08 3.89 1.17–12.98 0.03
Clarithromycin 1.45 1.26–1.68 < 0.001 3.17 1.08–9.28 0.04
Furosemide 1.72 1.63–1.82 < 0.001 2.03 1.01–4.08 0.05
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In the case of patients with severe COVID-19, dozens of drugs are prescribed simultaneously with hydroxy-
chloroquine, not only immunosuppressants or antibiotics. These drugs are medications that are taken regularly to 
treat chronic underlying diseases or are prescribed to relieve the patient’s symptoms without specific indications. 
Most of these drugs are known to have minimal effects on QT prolongation when administered individually, 
but there is a risk of prolonging the QT interval indirectly through DDI with hydroxychloroquine. To overcome 
this problem, we conducted a DDI study not only on selected drugs but for all drugs that were prescribed con-
currently with hydroxychloroquine in the chosen period. Consequently, the risk of prolonging the QT interval 
through DDI was observed in 12 drugs, even though the risk of QT prolongation in individual prescriptions 
was observed in only three drugs.
According to the therapeutic class of these drugs, three antibiotics (clarithromycin, piperacillin, and isoniazid) 
showed DDIs, and the mechanisms of these three antibiotics were also varied. Clarithromycin is a macrolide, 
Figure 2.  Interaction plots for 12 drugs that showed significant DDI with hydroxychloroquine. These plots 
show how the logit value (Y-axis) changes when the target drug (X-axis) is used alone and in combination 
with hydroxychloroquine. The 12 drugs plotted were drugs with statistically significant drug-drug interaction 
(DDI) in the iterative multiple logistic regression analysis. If there is a DDI, the two graphs have non-parallel 
slopes. In particular, when the interval between slopes increases, DDI exists in the direction of increasing QT 
prolongation. The interval between slopes increases in all 12 drugs.
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Table 3.  Ten drugs with the lowest p value of interaction terms for each subgroup. This table shows the 
ten drugs with the lowest p value of the interaction term with hydroxychloroquine in each subgroup. Each 
subgroup was divided into over 60 years old and under 60 years old or divided into male and female. ‘Single 
drug use’ columns show the odds ratio (OR), 95% confidence interval (95% CI), and p value of the analyzed 
drug in the linear regression, and ‘Interaction with hydroxychloroquine’ columns show OR, 95% CI, and the p 




OR 95% CI p value OR 95% CI p value
By age
Over 60
 Clopidogrel 1.013 0.947–1.083 0.708 0.42 0.175–1.009 0.052
 Bisoprolol 0.856 0.734–0.997 0.046 0.127 0.015–1.055 0.056
 Furosemide 1.445 1.346–1.551 < 0.0001 2.326 0.972–5.567 0.058
 Tramadol 1.004 0.81–1.245 0.972 2.604 0.876–7.738 0.085
 Trimebutine 0.924 0.799–1.069 0.288 1.754 0.903–3.406 0.097
 Cimetidine 1.054 0.949–1.171 0.322 0.287 0.064–1.283 0.102
 Amlodipine 0.94 0.867–1.02 0.136 0.551 0.247–1.231 0.146
 Chlorphenamine 1.085 0.981–1.199 0.112 0.398 0.115–1.38 0.147
 Diltiazem 0.813 0.739–0.894 < 0.0001 2.169 0.73–6.45 0.164
 Meloxicam 0.805 0.589–1.1 0.174 1.521 0.841–2.749 0.165
Equal to or under 60
 Rosuvastatin 0.864 0.755–0.989 0.034 7.253 2.437–21.587 < 0.0001
 Tramadol 0.916 0.8–1.049 0.203 2.506 1.587–3.959 < 0.0001
 Sulfasalazine 0.767 0.491–1.2 0.245 3.451 1.632–7.296 0.001
 Tacrolimus 0.593 0.438–0.804 0.001 3.52 1.709–7.25 0.001
 Trimebutine 0.774 0.654–0.916 0.003 2.558 1.238–5.285 0.011
 Ranitidine 1.199 1.103–1.303 < 0.0001 0.346 0.152–0.789 0.012
 Diltiazem 0.974 0.843–1.126 0.721 5.506 1.295–23.404 0.021
 Celecoxib 0.75 0.525–1.072 0.115 2.217 1.126–4.363 0.021
 Paracetamol 0.961 0.879–1.05 0.375 2.148 1.095–4.215 0.026
 Aceclofenac 0.739 0.572–0.954 0.02 2.146 1.071–4.299 0.031
By sex
Female
 Tramadol 0.926 0.819–1.046 0.217 1.809 1.254–2.612 0.002
 Trimebutine 0.837 0.72–0.973 0.02 2.29 1.344–3.905 0.002
 Nifedipine 1.297 1.116–1.509 0.001 2.828 1.252–6.387 0.012
 Sulfasalazine 0.801 0.477–1.345 0.402 2.508 1.179–5.334 0.017
 Celecoxib 0.76 0.64–0.904 0.002 1.716 1.08–2.728 0.022
 Tacrolimus 0.722 0.479–1.088 0.12 1.899 0.937–3.849 0.075
 Prednisolone 0.696 0.596–0.813 < 0.0001 1.512 0.911–2.51 0.11
 Furosemide 1.462 1.341–1.595 < 0.0001 1.971 0.843–4.611 0.117
 Aceclofenac 0.687 0.538–0.876 0.002 1.701 0.868–3.336 0.122
 Meloxicam 0.763 0.569–1.022 0.07 1.357 0.847–2.174 0.204
Male
 Tacrolimus 0.769 0.551–1.073 0.122 4.64 1.589–13.546 0.005
 Paracetamol 1.145 1.048–1.252 0.003 4.139 1.375–12.456 0.012
 Propacetamol 1.239 1.117–1.375 < 0.0001 7.962 1.585–40.01 0.012
 Nifedipine 1.361 1.185–1.564 < 0.0001 0.208 0.044–0.974 0.046
 Furosemide 1.934 1.79–2.09 < 0.0001 3.99 0.986–16.153 0.052
 Sulglicotide 0.814 0.574–1.155 0.248 3.665 0.982–13.679 0.053
 Atorvastatin 0.794 0.719–0.877 < 0.0001 2.919 0.953–8.942 0.061
 Clopidogrel 0.992 0.923–1.067 0.831 0.368 0.09–1.505 0.164
 Azathioprine 0.702 0.375–1.315 0.269 0.197 0.019–1.999 0.169
 Tramadol 1.023 0.909–1.152 0.704 1.569 0.817–3.015 0.176
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such as azithromycin. Therefore, a DDI between clarithromycin and hydroxychloroquine suggests the possibility 
of a DDI in the combined therapy of azithromycin and hydroxychloroquine, which was suggested as a COVID-
19  treatment20. In this study, azithromycin was not included since there was not a sufficient number of patients 
who used the drug concurrently with hydroxychloroquine. DDI studies for azithromycin would be required later 
using a more massive clinical database so this can be investigated further.
Besides, other antibiotics can also be lethal in diseases such as COVID-19, which is deeply associated with 
respiratory disease. Piperacillin is a drug commonly prescribed in the hospitalization of patients in intensive care 
units (ICU) due to respiratory diseases such as  pneumonia21. Isoniazid is a drug that is used to treat tuberculo-
sis, a disease that has a harmful effect on the lungs in the long term. As with COVID-19, tuberculosis is more 
common in developing  countries22. Therefore, if patients in developing countries have to treat tuberculosis and 
COVID-19 simultaneously, delicate QT interval monitoring is required.
Rofecoxib showed DDI with hydroxychloroquine in our main analysis, and several NSAIDs, such as celecoxib 
and paracetamol, showed interactions with hydroxychloroquine in the main analysis and in the young female 
subgroup analysis. Meanwhile, trimebutine, a spasmolytic drug commonly used for indigestion, showed DDI 
in the main analysis and in the young female subgroup analysis. These drugs are prescribed extensively and 
are often administered even in non-essential situations. Formerly, the side effects of these drugs are known to 
be minor. As a result, doctors are not cautious about these drugs, and they are often used as over-the-counter 
medicines. However, this study showed the possibility of DDI between these drugs and hydroxychloroquine, 
which could cause QT prolongation. Individually non-dangerous drugs could cause drug side effects due to DDI 
in environments where large amounts of drugs are co-administered, such as COVID-19. Unnecessary routine 
prescriptions should be reduced, and appropriate alternative drugs should be selected.
Tramadol, one of the most commonly prescribed opioids, also showed DDI interaction with hydroxy-
chloroquine. The risk of QT prolongation in opioids has already been  reported23. In particular, after COVID-
19, it became accessible to purchase drugs on a non-face-to-face basis, and so opioid use disorder is rapidly 
 increasing24,25. If patients with opioid use disorder are infected with COVID-19, it would be essential to prevent 
fatal cardiotoxic adverse effects through precise QT monitoring.
In the subgroup analysis, the drugs that showed DDIs differed substantially by subgroup. Only four drugs 
showed significant (p < 0.05) interactions in two or more subgroups among the drugs analyzed. These results 
suggest that the interaction of hydroxychloroquine with other drugs may vary by age and sex. However, the differ-
ence in the drugs showing interactions among subgroups could be due to the difference in prescription patterns 
for each subgroup. In the future, studies that focus on specific subgroups would require additional statistical 
methods to compensate for these prescription patterns.
It is common to manage DDIs in clinical practice, but the mechanisms of DDIs are not adequately understood. 
One possible hypothesis for the interaction of drugs is through the activity of the CYP 450  enzyme26. In the risk 
of QT prolongation interaction observed in this study, 7 out of 12 drugs had inhibitory effects on the metabolic 
pathway of hydroxychloroquine. CYP 450 2C8, and 3A4/5, especially clarithromycin and diltiazem, are known 
potent inhibitors of CYP 450  3A427. In addition, tramadol is also known to share the CYP 450 3A4 enzyme with 
 hydroxychloroquine28. These drugs may interfere with the metabolism of hydroxychloroquine, leading to QT 
prolongation by raising the hydroxychloroquine concentration to more than necessary.
This study has some limitations. First, it used a single institutional database. In the future, a multi-center study 
would be required to further generalize the results of this DDI study. Second, the drug dose information was 
not included in this study. If the drug dose information is used in future studies, it will be possible to investigate 
DDI changes according to the drug dose.
Conclusion
The current study investigated DDIs with hydroxychloroquine in 118 drugs using real-world data. We found sta-
tistically significant DDI in 12 drugs (trimebutine, tacrolimus, tramadol, rosuvastatin, cyclosporin, sulfasalazine, 
rofecoxib, diltiazem, piperacillin/tazobactam, isoniazid, clarithromycin, and furosemide) and the direction of 
the DDI was toward increasing the risk of QT prolongation. In eight drugs (trimebutine, tramadol, rosuvastatin, 
cyclosporin, sulfasalazine, rofecoxib, diltiazem, and isoniazid), DDI was present in the direction of increasing 
the risk of QT prolongation, even though the risk of QT prolongation was not observed with the use of those 
drugs alone.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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